0-7-21 hypofractionated palliative radiotherapy: an effective treatment for advanced head and neck cancers

We report our experience in providing palliative radiotherapy (RT) to patients with head and neck cancers (HNCs). Our hypofractionated regimen, "0-7-21", treats patients with 24 Gy in three fractions. Patients, disease and response data were retrieved for candidates of 0-7-21 from 2005 to...

Full description

Saved in:
Bibliographic Details
Published in:British journal of radiology 2015-05, Vol.88 (1049), p.20140646
Main Authors: Nguyen, N-T A, Doerwald-Munoz, L, Zhang, H, Kim, D-H, Sagar, S, Wright, J R, Hodson, D I
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Dose Fractionation
Female
Head and neck
Head and Neck Neoplasms - pathology
Head and Neck Neoplasms - radiotherapy
Humans
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Staging
Palliative Care
Prognosis
Radiotherapy and Oncology
Radiotherapy Dosage
Retrospective Studies
Survival Rate
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report our experience in providing palliative radiotherapy (RT) to patients with head and neck cancers (HNCs). Our hypofractionated regimen, "0-7-21", treats patients with 24 Gy in three fractions. Patients, disease and response data were retrieved for candidates of 0-7-21 from 2005 to 2012. Primary end points included symptom and tumour size responses to RT based on response evaluation criteria in solid tumours (RECIST) guidelines. Secondary end points included progression-free survival (PFS) within the irradiated field, overall survival (OS) and symptomatic PFS (SPFS), calculated using Kaplan-Meier method and adverse events. Cox proportional hazards regression and logistic regression were used to investigate for prognostic factors. A total of 110 patients were included. Among the patients, 40% and 31% had complete response for symptoms and tumour size, respectively; 42% and 50% had partial response for symptoms and tumour size, respectively; and 15% had stability of symptoms and tumour size. Median 6-month OS was 51%, and PFS within the irradiated field was 39%. Planning target volume was predictive of OS (p 
ISSN:0007-1285
1748-880X
DOI:10.1259/bjr.20140646